+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs



Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs



Clinical Pharmacokinetics 57(1): 1-6



The emergence of oral targeted anticancer agents transformed several cancers into chronic conditions with a need for long-term oral treatment. Although cancer is a life-threatening condition, oncology medication adherence-the extent to which a patient follows the drug regimen that is intended by the prescriber-can be suboptimal in the long term, as in any other chronic disease. Poor adherence can impact negatively on clinical outcomes, notably because most of these drugs are given as a standard non-individualized dosage despite marked inter-individual variabilities that can lead to toxic or inefficacious drug concentrations. This has been especially studied with the prototypal drug imatinib. In the context of therapeutic drug monitoring (TDM), increasingly advocated for oral anticancer treatment optimization, unreported suboptimal adherence affecting drug intake history may lead to significant bias in the concentration interpretation and inappropriate dosage adjustments. In the same way, suboptimal adherence may also bias the results of pharmacokinetic modeling studies, which will affect in turn Bayesian TDM interpretation that relies on such population models. Detailed knowledge of the influence of adherence on plasma concentrations in pharmacokinetic studies or in routine TDM programs is however presently missing in the oncology field. Studies on this topic are therefore eagerly awaited to better pilot the treatment of cancer with the new targeted agents and to find their optimal dosage regimen. Hence, the development and assessment of effective medication adherence programs are warranted for these treatments.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059645719

Download citation: RISBibTeXText

PMID: 28634655

DOI: 10.1007/s40262-017-0571-z


Related references

Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clinical Pharmacokinetics 41(6): 431-444, 2002

Adherence and patients' attitudes to oral anticancer drugs: a prospective series of 201 patients focusing on targeted therapies. Oncology 88(1): 1-8, 2015

Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats. Contraception 74(2): 165-173, 2006

Stereoselective separations of chiral anticancer drugs and their application to pharmacodynamic and pharmacokinetic studies. Therapeutic Drug Monitoring 15(6): 570-575, 1993

Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies. British Journal of Clinical Pharmacology 53(5): 553-553, 2002

Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Therapeutic Drug Monitoring 30(2): 173-180, 2008

Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clinical Cancer Research 12(18): 5481-5490, 2006

Adherence to targeted oral anticancer medications. Discovery Medicine 15(83): 231-241, 2013

Pharmacodynamic and pharmacokinetic inter-relationships of antibacterial drugs. Journal of veterinary pharmacology and therapeutics 20(1): 14-17, 1997

Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. Expert Opinion on Drug Delivery 2(3): 519-532, 2005

Oral 5-fluorouracil in psoriasis: pharmacokinetic-pharmacodynamic relationships. Pharmacology 39(2): 78-88, 1989

Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics 27(6): 503-514, 2004

Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clinical Pharmacokinetics 16(2): 100-128, 1989

Pharmacokinetic/pharmacodynamic relationships of ICI D1033 after single and multiple oral doses in man. Pharmaceutical Research (New York) 9(10 Suppl. ): S356, 1992

Retention pharmacokinetic and pharmacodynamic parameter relationships of antihistamine drugs using biopartitioning micellar chromatography. Journal of Chromatography B 761(1): 13-26, 15 September, 2001